Lucid Diagnostics announces proposed public stock offering

Lucid Diagnostics Inc. (NASDAQ: LUCD) announced its intention to offer shares of common stock through an underwritten public offering, according to a company statement. The medical diagnostics company, which is a subsidiary of PAVmed Inc. (NASDAQ: PAVM), also plans to grant underwriters a 30-day option to purchase additional shares.

The company stated that proceeds from the offering are expected to support working capital and general corporate purposes. Completion of the offering remains subject to market conditions, with no assurance regarding its timing, size, or terms.

Canaccord Genuity LLC and BTIG, LLC are serving as joint bookrunners of the offering, while Maxim Group LLC is acting as co-manager.

The offering is being conducted pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on December 6, 2022. A prospectus supplement relating to the offering will be filed with the SEC, together with an accompanying base prospectus.

Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company focused on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer. The company markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Banzai prices $0.9M public offering at $2.75 per share
• Samos Energy raises $230M in NYSE IPO for energy acquisitions